Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker 3.3)
Index Copernicus  – 161.11; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2006, vol. 15, nr 6, November-December, p. 1129–1138

Publication type: review article

Language: English

Low Molecular Weight Biomarkers in the Nephrotoxicity

Niskocząsteczkowe wskaźniki biochemiczne w diagnostyce nefrotoksyczności

Zofia Marchewka1,

1 Chair and Department of Toxicology, Laboratory of Environmental Nephrotoxicity Markers, Silesian Piasts University of Medicine, Wrocław, Poland

Abstract

The autor presents function and the diagnostics significance of urinary low molecular weight proteins and enzymes to evaluate kidney function. The markers, which allow to evaluate the function of the most sensitive renal tubules on the xenobiotics action, were chosen. They are: annexin V, α1−microglobulin (α1M), Clara cell protein (CC16), retinol binding protein (RBP), β2−microglobulin (β2M), cystatin C, lysozyme, lipocalin.

Streszczenie

W pracy przedstawiono funkcję i wartość diagnostyczną białek i enzymów niskocząsteczkowych w ocenie czynności nerek. Wybrano wskaźniki pozwalające ocenić stan i funkcję cewek nerkowych najbardziej wrażliwych na działanie ksenobiotyków. Do wskaźników tych należą: aneksyna V, α1−mikroglobulina (α1M), białko komórek Clara (CC16), białko wiążące retinol (RBP), β2−mikroglobulina (β2M), cystatyna C, lizozym, ludzka obojętnochłonna lipokalina (HNL).

Key words

nephrotoxicity, early markers, urine analysis

Słowa kluczowe

nefrotoksyczność, wczesne markery, analiza moczu

References (49)

  1. Sancewicz−Pach K, Ogarek I: Leki i substancje potencjalnie nefrotoksyczne. Przegl Lek 2001, 58, 4, 186–190.
  2. Klaassen CD: Casarett & Doull’s toxicology, The Basic Science of Poisons. International Edition, New York 1996, 14, 426–432.
  3. Kopeć M: Udział aneksyn w regulacji krzepnięcia krwi i fibrynolizy. Acta Haematol Pol 1998, 29, 2, 147–155.
  4. Ząbek J, Wojciechowska B, Alekberova Z, Reshetniak T, Biernacka E, Nasonova V, Karlik W: Przeciwciała dla aneksyny V jako nowy wskaźnik ryzyka zakrzepic i poronień w toczniu rumieniowatym układowym (SLE) oraz w zespole antyfosfolipidowym pierwotnym (PAPS) i wtórnym (SAPS). Reumatologia 2003, 41, 1, 12–24.
  5. Matsuda R, Kaneko N, Horikawa Y, Chiwaki F, Shinozaki M, Ieiri T, Suzuki T, Ogawa N: Localization of annexin V in rat normal kidney and experimental glomerulonephritis. Res Exp Med 2001, 200, 2, 77–92.
  6. Matsuda R, Kaneko N, Horikawa Y, Chiwaki F, Shinozaki M, Abe S, Yumura W, Nihei H, Ieiri T: Measurement of urinary annexin V by ELISA and its significance as a new urinary−marker of kidney disease. Clin Chim Acta 2000, 298, 29–43.
  7. Bengtsson AA, Sturfelt G, Gullstrand B, Truedsson L: Induction of apoptosis in monocytes and lymphocytes by serum from patients with systemic lupus erythematosus – an additional mechanism to increased autoantigen load? Clin Exp Immunol 2004, 135, 535–543.
  8. Allhorn M, Berggard T, Nordberg J, Asson ML, Akerstrom B: Processing of the lipocalin α1−microglobulin by hemoglobin induces heme−binding and heme−degradation properties. Blood 2002, 99, 6, 1894–1901.
  9. Akerstrom B, Logdberg L, Berggard T, Osmark P, Lindgvista A: α1−microglobulin: a yellow−brown lipokalin. Biochim Biophys Acta 2000, 1482, 172–174.
  10. Mantur M, Kemona H, Dąbrowska M, Dąbrowska J, Sobolewski S, Prokopowicz J: Alpha1−microglobulin as a marker of proximal tubular damage in urinary tract infection in children. Clin Nephrol 2000, 53, 4, 283–287.
  11. Hong CY, Hughes K, Chia KS, Ng V, Ling SL: Urinary alpha1−microglobulin as a marker of nephropathy in type 2 diabetic Asian subjects in Singapure. Diabetes Care 2003, 26, 338–341.
  12. Holdt−Lehmann B, Lehmann A, Korten G, Nagel HR, Nizze H, Schuff−Werner P: Diagnostic value of urinary alanine aminopeptidase and N−acetyl−β−D−glucosaminidase in comparison to α1−microglobulin as a marker in evaluating tubular dysfunction in glomerulonephritis patients. Clin Chim Acta 2000, 297, 93–102.
  13. Moriguchi J, Ezaki T, Tsukahara T, Furuki K, Fukui Y, Okamoto S, Ukai H, Sakurai H, Stumbo S, Ikeda M: Comparative evaluation of four urinary tubular dysfunction markers with special references of aging and correction for creatinine concentration. Toxicol Lett 2003, 143, 279–290.
  14. Herman MB, Lammert M, Selinski S, Brüning T: Urinary α1−microglobulin excretion as biomarker of renal toxicity in trichloroethylene−exposed persons. Int Arch Occup Environ Heath 2004, 77, 186–190.
  15. Bernard A, Lauwerys R: Low−molecular−weight proteins as markers of organ toxicity with special reference to Clara cell protein. Toxicol Lett 1995, 77, 145–151.
  16. Bernard AM, Thielemans NO, Lauwerys RR: Urinary protein 1 or Clara cell protein: a new sensitive marker of proximal tubular dysfunction. Kidney Int 1994, 47, 34–37.
  17. Shijubo N, Kawabata I, Sato N, Itoh Y: Clinical Aspects of Clara Cell 10−kDa Protein/Uteroglobin (Secretoglobin 1A1). Curr Pharm Des 2003, 9, 14, 1139–1149.
  18. Raghu P, Ravinder P, Sivakumar B: Anew method for purification of human plasma retinol−binding protein and transthyretin. Biotechnol Appl Biochem 2003, 38, 19–24.
  19. Yamada K, Matsuoka Y, Yamamoto A, Kawana T, Ishii K, Ishimi Y, Ikegami S: Elevation of plasma retinol binding protein concentration in experimental acute renal failure. Nutr Res 1997, 17, 10, 1555–1567.
  20. Sundaram M, Aalten D, Findlay J, Sivaprasadarao A: The transfer of transthyretin and receptor−binding properties from the plasma retinol−binding protein to the epididymal retinoic acid−binding protein. Biochem J 2002, 362, 265–269.
  21. Camara NO, Silva MS, Nishida S, Pereira AB, Pacheco−Silva A: Proximal tubular dysfunction is associated with chronic allograft nephropathy and decreased long−term renalgraft survival. Transplantation 2004, 78, 269–275.
  22. Kirsztajn GM, Nishida SK, Silva MS, Azjen H, Pereira AB: Urinary retinol binding protein as a prognostic marker in the treatment of nephrotic syndrome. Nephron 2000, 86, 109–114.
  23. Bang LE, Holm J, Svendsen T: Retinol−Binding Protein and Transferrin in Urine. New Markesr of Renal Function in Essential Hypertension and White Coat Hypertension? Am J Hypertens 1996, 9, 1024–1028.
  24. Buchet JP, Heilier JF, Bernard A, Lison D, Jin T, Wu X, Kong Q, Nordberg G: Urinary protein excretion in humans exposed to arsenic and cadmium. Int Arch Occup Environ Health 2003, 76(2), 111–120.
  25. De Burbure C, Buchet JP, Bernard A, Leroyer A, Nisse C, Haguenoer JM, Bergamaschi E, Mutti A: Biomarkers of renal effects in children and adults with low environmental exposure to heavy metals. J Toxicol Environ Health A 2003, 66, 783–798.
  26. Weaver VM, Lee BK, Todd AC, Jaar BG, Ahn KD, Wen J, Shi W, Parsons PJ, Schwartz BS: Associations of patella lead and other lead biomarkers with renal function in lead workers. J Occup Envirin Med 2005, 47, 235–243.
  27. Voss JU, Roller M, Brinkmann E, Mangelsdorf I: Nephrotoxicity of organic solvents: biomarkers for early detection. Int Arch Occup Environ Health 2005, 78, 475–485.
  28. Kamieńska A, Jung A, Olszewski S: β2−mikroglobinuria u dzieci z odpływami pęcherzowo−moczowymi i nawracającymi zakażeniami układu moczowego. Pol Merk Lek 2000, 8, 240–241.
  29. Wiela−Hojeńska A, Hurkacz M: Znaczenie β2−mikroglobuliny w diagnostyce i terapii. Postepy Hig Med Dośw 1998, 52, 507–514.
  30. Kuźniar J, Marchewka Z, Krasnowski R, Długosz A, Klinger M: Wykorzystanie wydalania w moczu białek drobnocząsteczkowych oraz enzymów jako wskaźników uszkodzenia śródmiąższowego w glomerulopatiach. Adv Clin Exp Med 2003, 12, 305–313.
  31. Marchewka Z, Kuźniar J, Długosz A: Enzymuria and β2−mikroglobulinuria in the assessment of the influence of proteinuria on the progression of glomerulopathies. Int Urol Nephrol 2001, 33, 673–676.
  32. Marchewka Z: Wartość diagnostyczna transferaz glutationowych i innych parametrów biochemicznych w moczu jako wczesnych wskaźników uszkodzenia nerek. Diagn Lab 2004, 40, 567–572.
  33. Marchewka Z, Długosz A: Wybrane wskaźniki biochemiczne w moczu w ocenie funkcji nerki pracowników narażonych na benzynę. Bromat Chem Toksykol 2003, 36, 155–159.
  34. Warwas M, Murawska E: Ludzka cystatyna C. Diagn Lab 1991, 27, 71–73.
  35. Filler G, Bokenkamp A, Hofman W, Le Bricon T, Martinez−Bru C, Grubb A: Cystatin C as a marker of GFR−history, indications, and future research. Clin Biochem 2005, 38, 1–8.
  36. Grubb A: Cystatin C−Properties and use as diagnostic marker. Adv Clin Chem 2001, 35, 64–91.
  37. Mussap M, Plebani M: Biochemistry and Clinical Role of Human Cystatin C. Crit Rev Clin Lab Sci 2004, 41, 467–550.
  38. Bardi E, Bobok I, Olah VA, Olah E, Kappelmayer J, Kiss C: Cystatin C is a suitable marker of glomerular function in children with cancer. Pediatr Nephrol 2004, 19, 1145–1147.
  39. Piwowar A, Warwas M: Cystatyna C jako wskaźnik przesączania kłębuszkowego nerek. Postepy Hig Med Dosw 2001, 55, 687–695.
  40. Uchida K, Gotoh A: Measurement of cystatin−C and creatinine in urine. Clin Chim Acta 2002, 103, 121–128.
  41. Jung K, Mattenheimer H, Burchardt U: Urinary enzymes in clinical and experimental medicine. Springer−Verlag, Berlin 1992.
  42. Hrycek A, Szołtysik I, Grzeszczak W: Aktywność lizozymu w surowicy krwi nierozcieńczonej i rozcieńczonej u chorych po przeszczepie nerki leczonych cyklosporyną A z prednizonem lub azatiopryną z prednizonem. Pol Arch Med Wewn 1992, 88, 12–17.
  43. Price RG: Early markers of nephrotoxicity. Comp Clin Path 2002, 11, 1–7.
  44. Coles M, Diercks T, Muehlenweg B, Bartsch S, Zölzer V, Tschesche H, Kessler H: The Solution Structure and Dynamics of Human Neutrophil Gelatinase Associated Lipocalin. J Mol Biol 1999, 289, 139–140.
  45. Flower D: The lipocalin protein family: structure and function. Biochem J 1996, 318, 1–14.
  46. Mishra J, Qing MA, Prada A, Mitsnefes M, Zahedi K, Yang J , Barasch J, Devarajan P: Identification of neutrophil gelatoicnase−associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003, 14, 2534–2539.
  47. Xu S, Venge P: Lipocalins as biochemical markers of disease. Biochim Biophys Acta 2000, 1482, 303–304.
  48. Mishra J, Dent K, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Sheo M, Bean J, Mori K, Barasch J, Devarajan P: Neutrophil gelatinase−associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005, 365, 1231–1238.
  49. Mishra J, Mori K, Ma Q, Kelly C, Barasch J: Neutrophil Gelatinase−Associated Lipocalin: A Novel Early Urinary Biomarker for Cisplatin Nephrotoxicity. Am J Nephrol 2004, 24, 307–315.
© Wroclaw Medical University